Clinical trials: Chronic Rhinosinusitis With Nasal Polyps
Chronic Sinusitis, Nasal Polyposis
S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps
The RESOLVE II Study is a randomized, single-blind, parallel arm, concurrently controlled, multicenter study with 300 chronic sinusitis patients who had prior endoscopic sinus surgery but present with recurrent sinus obstruction.
- Trial name
- RESOLVE_II (NCT02291549)
- Testing
- S8 Sinus Implant, Mometasone furoate nasal spray
- Where
- 40 sites in United States
- Volunteers
- 300 people
- Sponsor
- Intersect ENT
Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
EFC18418 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups.
- Trial name
- CEREN-1 (NCT06834347)
- Testing
- Itepekimab (SAR440340), Mometasone furoate nasal spray (MFNS)
- Where
- 121 sites in United States, Argentina and 19 more
- Volunteers
- 231 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
EFC18419 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups.
- Trial name
- CEREN-2 (NCT06834360)
- Testing
- Itepekimab (SAR440340), Mometasone furoate nasal spray (MFNS)
- Where
- 111 sites in United States, Argentina and 21 more
- Volunteers
- 216 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
This is a parallel, Phase 2, 2-arm, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study for treatment of CRSwNP.
- Trial name
- NCT06454240
- Testing
- lunsekimig
- Where
- 29 sites in United States, Argentina and 4 more
- Volunteers
- 79 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyposis
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）
This is an open-label, single-arm, multicenter, extension study to evaluate the safety and efficacy of CM512 in patients With Chronic Rhinosinusitis with Nasal Polyposis
- Trial name
- NCT07519577
- Testing
- CM512
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Keymed Biosciences Co.Ltd
Chronic Rhinosinusitis With Nasal Polyps
The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps
This is an open-label, single-arm, multicenter, extension study to evaluate the long-term safety and efficacy of GR1802 injection in patients with Chronic Rhinosinusitis With Nasal Polyps
- Trial name
- NCT06015243
- Testing
- GR1802 injection
- Volunteers
- 70 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Chronic Rhinosinusitis Without Nasal Polyps
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
ACT18421 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups.
- Trial name
- NCT06691113
- Testing
- Itepekimab (SAR440340), Mometasone furoate nasal spray (MFNS)
- Where
- 57 sites in United States, Argentina and 11 more
- Volunteers
- 66 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps
The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and to…
- Trial name
- VIBRANT (NCT06164704)
- Testing
- Verekitug (UPB-101)
- Where
- 41 sites in United States, Czechia and 3 more
- Volunteers
- 81 people
- Sponsor
- Upstream Bio Inc.
Chronic Rhinosinusitis With Nasal Polyps
The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps
This is an open-label, single-arm, multicenter, extension study to evaluate the long-term safety and efficacy of CM310 in patients with CRSwNP.
- Trial name
- NCT05131464
- Testing
- CM310
- Where
- 3 sites in China
- Volunteers
- 46 people
- Sponsor
- Keymed Biosciences Co.Ltd
Nasal Polyps
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- ANCHOR-2 (NCT05281523)
- Testing
- Depemokimab (GSK3511294)
- Where
- 84 sites in United States, China and 7 more
- Volunteers
- 264 people
- Sponsor
- GlaxoSmithKline
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab in Chinese Adult Participants With CRSwNP
This is a parallel group, Phase 3, 2-arm study for treatment. The purpose of this study is to evaluate dupilumab subcutaneous (SC) injections compared to placebo in Chinese adult participants with CRSwNP, on a background therapy…
- Trial name
- NCT05878093
- Testing
- Dupilumab, Budesonide
- Where
- 18 sites in China
- Volunteers
- 63 people
- Sponsor
- Sanofi
Chronic Sinusitis, Nasal Polyposis
Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)
The ENCORE Study is designed to evaluate the repeat administration of the S8 Sinus Implant in chronic sinusitis (CS) patients with recurrent nasal polyps.
- Trial name
- NCT03358329
- Testing
- S8 Sinus Implant
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Intersect ENT
Chronic Rhinosinusitis With Nasal Polyps
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma. Study details include: 1.
- Trial name
- ESSENCE (NCT06706817)
- Testing
- Tezepelumab
- Where
- 41 sites in United States, Bulgaria and 7 more
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus…
- Trial name
- ORCHID (NCT04157335)
- Testing
- Benralizumab 30 mg
- Where
- 116 sites in United States, Argentina and 15 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis (Diagnosis), Nasal Polyps
Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1)
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of CM310 in comparison to placebo in addition to a background treatment of mometasone furcate…
- Trial name
- NCT04805398
- Testing
- CM310
- Where
- 19 sites in China
- Volunteers
- 56 people
- Sponsor
- Keymed Biosciences Co.Ltd
Chronic Rhinosinusitis
Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A study to evaluate the safety and efficacy of multiple doses of etokimab in adults with chronic rhinosinusitis with nasal polyps.
- Trial name
- NCT03614923
- Testing
- Etokimab, Mometasone Furoate Nasal Spray
- Where
- 28 sites in United States
- Volunteers
- 105 people
- Sponsor
- AnaptysBio, Inc.
Chronic Sinusitis With or Without Nasal Polyps
Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or…
- Trial name
- NCT01623323
- Testing
- Fluticasone Propionate
- Where
- 18 sites in United States
- Volunteers
- 705 people
- Sponsor
- Optinose US Inc.
Chronic Rhinosinusitis With Nasal Polyps
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
This is a multicentre, open-label, single-arm, Phase 3b study to assess nasal polyps score and symptoms in Chinese adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab.
- Trial name
- BIFANG (NCT07520162)
- Testing
- Tezepelumab
- Where
- 34 sites in China
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps
A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps
This is a multi-center, randomized, double blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of CM326 in patients with chronic rhinosinusitis…
- Trial name
- DUBHE (NCT05324137)
- Testing
- CM326
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Keymed Biosciences Co.Ltd
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
- Trial name
- NCT06338995
- Testing
- LY3650150, Standard therapy for INCS
- Where
- 202 sites in United States, Argentina and 18 more
- Volunteers
- 510 people
- Sponsor
- Eli Lilly and Company